China
Africa
Explore chapters and articles related to this topic
Embolization for fistulas and arteriovenous malformations
Published in Debabrata Mukherjee, Eric R. Bates, Marco Roffi, Richard A. Lange, David J. Moliterno, Nadia M. Whitehead, Cardiovascular Catheterization and Intervention, 2017
Nicholas Kipshidze, Robert J. Rosen, Irakli Gogorishvili
Glue or tissue adhesives, such as N-butyl cyanoacrylate (n-BCA) and isobutyl cyanoacrylate, are another category of liquid embolic agents that polymerize on contact with an ionic environment, such as blood. In experienced hands, these are very effective for AVM occlusion, but require frequent, time- consuming catheter exchanges, and as with ethanol, great care should be taken to avoid nontarget embolization.
Poly(Alkyl Cyanoacrylate) Nanoparticles for Delivery of Anti-Cancer Drugs
Published in Mansoor M. Amiji, Nanotechnology for Cancer Therapy, 2006
R. S. R. Murthy, L. Harivardhan Reddy
This technique is widely used for the preparation of nanoparticles by the polymerization of a wide variety of monomers, including alkylcyanoacrylates. Employing very low quantities of surfactants, it is only used to stabilize the newly formed polymer particles. Apart from this, the polymerization of alkylcyanoacrylates has also been carried out in the absence of surfactants,15 in aqueous media containing dextran or hydroxylpropyl-β-cyclodextrin (HPCD). Poly(ethyl cyanoacrylate) and poly(isobutyl cyanoacrylate) (PIBCA) nanospheres containing metaclopramide have been prepared using this technique. However, the resulting drug loading was only 9.2% and 14.8%, respectively.
Surface-modified polymeric nanoparticles for drug delivery to cancer cells
Published in Expert Opinion on Drug Delivery, 2021
Arsalan Ahmed, Shumaila Sarwar, Yong Hu, Muhammad Usman Munir, Muhammad Farrukh Nisar, Fakhera Ikram, Anila Asif, Saeed Ur Rahman, Aqif Anwar Chaudhry, Ihtasham Ur Rehman
During circulation in the bloodstream, conventional nanoparticles are usually opsonized and captured by the mononuclear phagocytes system (MPS), e.g., liver, spleen, lungs, and bone marrow [4]. These are unfavorable sites of actions for most anticancer drugs. Therefore, the interaction of nanoparticles with these organs could produce detrimental effects; for example, such nanoparticles could target bone marrow and increase myelosuppressive effects as it was reported in doxorubicin-loaded poly(isobutyl cyanoacrylate) nanoparticles [5]. Surface-modified nanoparticles are designed to minimize these nonspecific interactions with blood components and MPS organs, and precisely target cancer tissues. These nanoparticles enter the tumor tissue, escape from cellular barriers, and release the anticancer drug in cells [6] (Figure 1).
A journey through the emergence of nanomedicines with poly(alkylcyanoacrylate) based nanoparticles
Published in Journal of Drug Targeting, 2019
Another clinical trial was achieved on PACA nanoparticles in China during the years 2000 (Sichua Food and Drug Administration 1999-266). This was a phase II that have evaluated mitoxanthrone (dihydroxyanthracenedione)-loaded poly(isobutyl cyanoacrylate) (DHAD-PIBCA) nanoparticles in a treatment of HCC using an intravenous slow injection (at least 15 min) [91]. It has included 108 patients. This clinical study has also demonstrated the feasibility of an intravenous administration of PACA nanoparticles to human. A benefit for the patients in terms of survival was reported compared with the control arm including patients who received injections of the free drug. Although promising for patients with unresected HCC, no record for further clinical trial or publication could be found in the recent literature suggesting that the work was not pursued.